Navigation Links
Drug Company Admits Knowledge Of Side Effects In Monkeys

TeGenero, a German based drug firm that had manufactured TGN-1412, has now admitted that the drug had showed adverse effects//, when tested on monkeys. Four out of the six who were admitted to the intensive care unit of a London based hospital following the drug administration are recovering, according to official reports.

The controversial clinical trial had been conducted at Northwick Park Hospital in Harrow, London. Two of the six volunteers are still under a critical condition. Organ support is being provided to two other study participants. The rest two are off their support systems.

In a pre-clinical trial that involved animals, two monkeys have been reported to develop lymph node inflammation following injection of the experimental drug. The company in response to the above issue has however said that symptoms experienced by the man had no correlation with that documented in monkeys.

'There were adverse effects in a certain dosage. Some of the monkeys developed an increase in the lymph nodes,' said Prof. Johannes Loewer, President, Paul Ehrlich Institute.

The drug company had previously claimed that there had been no drug-related adverse effects. Furthermore, the study participants were told that there had been no instances of adverse effects in the prior tests. The side effect of the drug as seen in monkeys had been high enough to warrant monitoring of the immune system and function in human volunteers.

A previous study conducted in 2002 had warned about the possible risks associated with TGN-1412, much earlier. Human cells subjected to treatment with the drug under experimental conditions were found to suffer a significant level of damage.

Health officials have now questioned how the British authority, could have approved of the human clinical trials of the experimental drug despite the known health hazard. 'We assigned expert assessors to review the original decision in approving the cli nical trial and we found nothing that would question our decision,' said Silke Thomson, spokeswoman, Medicines and Healthcare Products Regulatory Agency, in a response statement.


Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Ranbaxy Expands By Acquiring A Generic Company In Belgium
8. Indian Training Company To Train Children In Dubai, Sharjah
9. GE Healthcare to Acquire Swedish Medical Company
10. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
11. New Company Will Seek Drugs Against Diabetes and Cancer
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
(Date:12/1/2015)... Hills, CA (PRWEB) , ... December 01, 2015 ... ... by Modern Luxury’s Angeleno Magazine as a Modern Man for 2015. , ... lifestyle publisher in the United States. Established in 1994, Modern Luxury includes more ...
(Date:11/30/2015)... Cary, NC (PRWEB) , ... November 30, 2015 , ... ... and corporate support as they play for the chance to represent the United States. ... fans the opportunity to be a part of their journey in addition to offering ...
(Date:11/30/2015)... ... November 30, 2015 , ... 1Heart Caregiver Services’ Executive ... Federation of Philippine American Chambers of Commerce held from November 6-8, 2015 at ... Caregiver Services, as an active delegate from the Philippine American Chamber of Commerce ...
(Date:11/30/2015)... ... ... Stress, anxiety, illness, infection or even a need for eyeglasses can sometimes cause ... a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, Florida, said that ... “Bad headaches that don’t go away, that don’t have any other reason, even ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 /PRNewswire/ ... its wholly-owned UK subsidiary Proximagen Ltd., today announced a ... oral small molecule inhibitor of Vascular Adhesion Protein 1 ... the treatment of inflammatory disease. The VAP-1 inhibitor is ... --> --> Under the terms of ...
(Date:11/30/2015)... TOKYO , 1 décembre 2015 ... plus grande exposition et conférence d,Asie ... médicaux et sur l,industrie manufacturière, se ... du 20 au 22 avril ... - Photo - ...
(Date:11/30/2015)... 2015 --> ... - Pipeline Review, H2 2015" market research ... pipeline of Endometriosis and helps enhance decision ... to gain competitive advantage. It strengthens R&D ... to produce first-in-class and best-in-class products. ...
Breaking Medicine Technology: